Episode 61
Biotech Hangout
00:00
Gilead's 21 Billion for Chordelvie
There were some like microcap movers when abstracts came out like a week ago. People are also focused on another checkpoint, leg three, which is actually already approved in melanoma. Cardo went head to head against dem cell transplant in this second line, large B cell lymphoma. Janssen and legend with their BCMA CAR-T are going into earlier lines of setting multiple myelomas. But the main headline is that many doubters said it'll either never work or will only work very late stage refractory patients. And I think these abstracts are proving that wrong.
Transcript
Play full episode
